Researchers screened patients for mixed strain pathogen infections as part of a clinical trial and found that “at least 1/3 of patients are colonized by multiple Pseudomonas strains, and that resistance evolves rapidly in these patients due to selection for pre-existing resistant strains.”
They suggest additional investigation to fully understand this link but suggest that taking measurements on the diversity of a pathogen population could allow experts to “more accurately predict the likelihood of treatment failure at the level of individual patients,” the study authors wrote.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
